Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Center, Korea
University of Kentucky
Eastern Cooperative Oncology Group
City of Hope Medical Center
Janssen Research & Development, LLC
Memorial Sloan Kettering Cancer Center
Washington University School of Medicine
National Cancer Institute (NCI)
University of Southern California
University of Chicago
First Affiliated Hospital of Wenzhou Medical University
Centre Francois Baclesse